iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers

NEXT STORY
MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors
PREV STORY
Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product, By Test Location, By Technology, By Application, By Region And Segment Forecasts, 2020 – 2027
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MPI – Clinical data on PARP inhibitor 2X-121 and DRP response prediction validation to be presented on the world’s largest cancer congress ASCO 2018

Hoersholm, Denmark, June 1, 2018 - Medical Prognosis Institute A/S ("MPI") hereby announces that ...

author_avatar
NASDAQ Market News

Point of Care (POC) Molecular Diagnostics Market Worth $2.39 Billion by 2027, Growing at a CAGR of 13.2% from 2019- Pre and Post COVID-19 Market Opportunity Analysis and Industry Forecasts by Meticulous Research®

author_avatar
NASDAQ Market News

BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials

author_avatar
NASDAQ Market News